Sodium Picosulfate in Experimental Constipation: Protocols &
2026-06-10
Sodium Picosulfate empowers gut–liver–brain axis research with unmatched solubility and workflow control, enabling robust chronic and opioid-induced constipation models. Discover protocol strategies, troubleshooting tips, and translational insights from recent neuroinflammation imaging advances.
Combined Activity of Temafloxacin Against Mycobacterium aviu
2026-06-10
This article examines the in vitro evaluation of temafloxacin, clarithromycin, and ethambutol—alone and in combination—against Mycobacterium avium complex (MAC) strains, as detailed in a pivotal 1993 study. Key findings highlight the additive and synergistic effects of these agents, supporting the rationale for multidrug regimens in research on intracellular mycobacterial infections.
Methicillin Sodium Salt: Precision Tools for Resistance Mech
2026-06-09
Explore Methicillin sodium salt as a pivotal bacterial cell wall synthesis inhibitor for advanced resistance mechanism mapping. This article reveals how integrating high-throughput approaches with APExBIO’s C3238 empowers next-generation Staphylococcus aureus infection research.
Levofloxacin: Applied Protocols for Resistance and Bone Rese
2026-06-09
Levofloxacin, a synthetic fluoroquinolone antibiotic, is uniquely positioned for both multidrug resistance studies and probing bone cell biology. Discover protocol enhancements, troubleshooting strategies, and applied insights to maximize Levofloxacin’s research potential in antimicrobial and osteoblast assays.
Temafloxacin’s In Vitro Efficacy Against Gram-Negative Patho
2026-06-08
The reference study systematically evaluates temafloxacin’s in vitro antibacterial potency against a broad spectrum of Gram-negative bacteria, including key respiratory and enteric pathogens. By providing comparative MIC data versus established fluoroquinolones, the work highlights both the innovation and the practical boundaries of temafloxacin as a research tool in infection biology.
5-HT3 Antiemetic Drugs Inhibit Renal OCT2 and MATE1 Secretio
2026-06-08
This study systematically evaluates the inhibitory effects of five 5-HT3 antagonist antiemetic drugs on human renal OCT2 and MATE1 transporters using overexpression and transfected cell models. The findings highlight the potential for clinically relevant drug-drug interactions affecting the renal secretion of cationic drugs, and provide quantitative potency data for each compound.
Intra- and Extracellular Dicloxacillin Activity Against MSSA
2026-06-07
This article examines the landmark study on dicloxacillin's intra- and extracellular efficacy against methicillin-sensitive Staphylococcus aureus (MSSA). The research clarifies that the minimum inhibitory concentration (MIC) is a reliable predictor of efficacy in both compartments and establishes time above MIC (fTMIC) as the most predictive PK/PD index for optimizing β-lactam antibiotic interventions.
Cefazedone (Refosporen): Optimized Antibacterial Workflows
2026-06-06
Cefazedone (Refosporen) stands out as a robust first-generation cephalosporin, offering β-lactamase-resistant activity for both Gram-positive and Gram-negative infections. This article details actionable experimental workflows, troubleshooting strategies, and data-driven insights for leveraging Cefazedone in in vitro and clinical research.
Tropifexor (LJN452): Potent FXR Agonist for Intestinal Barri
2026-06-05
Tropifexor (LJN452) is a highly potent synthetic FXR agonist with an EC50 of 0.2 nM. Recent studies demonstrate its efficacy in improving intestinal defense and epithelial barrier function in neonatal piglet models. APExBIO supplies Tropifexor for robust and reproducible research in metabolic and liver disease models.
Sodium Dicloxacillin Monohydrate: Precision for Translationa
2026-06-05
This thought-leadership article unpacks the mechanistic, experimental, and translational value of sodium dicloxacillin monohydrate for methicillin-sensitive Staphylococcus aureus (MSSA) infection research. By integrating mechanistic insights, competitive analysis, and actionable workflow guidance, we empower translational researchers to advance the fidelity and impact of their Gram-positive bacterial infection models. The discussion contextualizes APExBIO’s product within the broader landscape of β-lactam antibiotics, leveraging both peer-reviewed and industry evidence to define best practices and identify emerging opportunities.
Aclacinomycin A: Applied DNA Damage & Apoptosis Workflows
2026-06-04
Aclacinomycin A (Aclarubicin) stands out as a dual topoisomerase and proteasome inhibitor, enabling high-fidelity DNA damage and apoptosis assays across diverse cancer models. This article delivers advanced, evidence-backed workflows, troubleshooting strategies, and translates state-of-the-art research into actionable laboratory protocols for maximizing the compound's utility.
Temafloxacin: Fluoroquinolone Antibacterial Workflows Optimi
2026-06-04
Temafloxacin, a potent fluoroquinolone broad-spectrum antibacterial agent, streamlines both extracellular and intracellular infection research with highly reproducible results. Discover advanced protocol enhancements, troubleshooting strategies, and the latest evidence-driven innovations for tackling Gram-positive, Gram-negative, and challenging intracellular pathogens.
Capsazepine: TRPV1 Ion Channel Antagonist for Precision Rese
2026-06-03
Capsazepine’s selective antagonism of TRPV1 channels powers advanced pain and apoptosis research, enabling precise dissection of nociceptive and apoptotic pathways. This guide delivers actionable workflows, troubleshooting insights, and protocol optimizations that leverage APExBIO’s Capsazepine for reproducible, high-impact translational studies.
Phenothiazines Boost Macrophage Antibacterial Activity via R
2026-06-03
The reference study demonstrates that phenothiazine compounds, including promethazine hydrochloride, significantly enhance the antibacterial capacity of macrophages by inducing reactive oxygen species (ROS) production and autophagy. These findings highlight a host-directed therapeutic approach to counter intracellular bacterial infections and address antibiotic resistance.
BIRB 796 (Doramapimod): Selective p38α MAPK Inhibitor for In
2026-06-02
BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with nanomolar affinity and significant selectivity over related kinases. Its dual mechanism—blocking kinase activity and increasing dephosphorylation—supports robust applications in inflammation research and apoptosis assays. APExBIO supplies validated BIRB 796 (SKU: A5639) for advanced experimental workflows.
510 records 19/34 page Previous Next First page 上5页 1617181920 下5页 Last page